Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
New Delhi, Jan 6 (PTI) Homegrown pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic version of sulfamethoxazole and trimethoprim oral suspension used in the treatment of bacterial infections.
Sulfamethoxazole and trimethoprim oral suspension, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (for example, middle ear, urine, respiratory, and intestinal infections), and certain sort of pneumonia (pneumocystis-type).
Citing IQVIA MAT September 2020 data, the company said the sulfamethoxazole and trimethoprimoral suspension had estimated annual sales of about USD 19 million in the usa. PTI RKL MKJ
